ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 15.5% from a year ago

Net receivables stood at $161.02M at the end of Q3 FY2026, up 15.5% from a year earlier and down 3.2% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.

Context

  • Net receivables amounted to 9.0% of total assets at the end of Q3 FY2026, down 1.5 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +15.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$161.02M-3.2% QoQ
Last fiscal yearDec 2025
$148.23M+41.6% YoY
Year agoSep 2025
$139.44M+15.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.5%——
1 year+41.6%——
3-year CAGR+32.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
148.23M USD
Year-over-year change
+41.6%
4-year CAGR
+22.7%

Net Receivables vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's Sep 2026 net receivables of $161.02M is the 2nd highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +15.5% is the 3rd highest of 4, against a peer median of +27.5%.
  • Net receivables amounts to 9.0% of total assets for ACAD, versus a peer median of 0.0%.
ACAD Competitors Peer median
Net Receivables for ACAD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AXSMAxsome Therapeutics, Inc.Jun 2026$277.46M +39.5%+81.2%36.4%
ACADACADIA Pharmaceuticals Inc.Sep 2026$161.02M +15.5%+32.9%9.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$56.88M +27.5%+17.7%13.1%
AVXLAnavex Life Sciences Corp.Dec 2025$844K -67.0%-36.7%0.6%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$58K ——0.0%
PRAXPraxis Precision Medicines, Inc.Sep 2026$0 ——0.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$0 ——0.0%
ANROAlto Neuroscience, Inc.Mar 2026$0 ——0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$0 ——0.0%
MPLTMapLight Therapeutics, Inc.Mar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding ACAD) $0+27.5%+17.7%0.0%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents147.44M114.85M188.66M319.59M177.7M
Short-term Investments373.27M301.98M250.21M436.4M641.99M
Net Receivables65.34M63.08M102.35M104.7M148.23M
Inventory7.88M6.64M35.82M21.95M34.67M
Other Current Assets00000
Total Current Assets617.82M507.94M616.13M938.32M1.06B
Property, Plant & Equipment (Net)66.32M61.59M56.47M50.79M54.87M
Goodwill00000
Intangible Assets0065.49M119.78M108.89M
Long-term Investments3.6M12.97M5.77M8.77M7.85M
Tax Assets0000249.88M
Other Non-current Assets12.38M5.31M5.1M70.1M80.6M
Total Non-current Assets82.3M79.88M132.83M249.44M502.08M
Total Assets700.12M587.81M748.96M1.19B1.56B
Account Payables6.88M12.75M17.54M16.19M10.9M
Short-term Debt009.41M011.63M
Tax Payables0377K1.56M12.02M0
Deferred Revenue00000
Other Current Liabilities25.9M49.51M92.31M36.55M67.83M
Total Current Liabilities96.07M125.63M254.25M394.87M277.11M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.03M9.07M15.15M18.06M19.14M
Total Non-current Liabilities63.16M61.77M62.95M60.09M59.69M
Total Liabilities159.23M187.4M317.2M454.96M336.81M
Common Stock16K16K16K16K16K
Retained Earnings(2.15B)(2.37B)(2.43B)(2.2B)(1.81B)
Accumulated OCI(192K)(975K)24K292K1.45M
Other Stockholders Equity00000
Minority Interest00000
Total Equity540.89M400.41M431.76M732.79M1.23B
Total Debt64.43M62M57.21M52M52.19M
Net Debt(83.01M)(52.85M)(131.45M)(267.59M)(125.51M)

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.